Intervention not reported
Immunoglobulins (Direct evidence; 3 RCTs; 243 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
It is very uncertain whether the intervention changes immunoglobulins (Direct evidence; 3 RCTs; 243 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Interferon beta 1a‐1b No direct evidence · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
It is very uncertain whether the intervention changes interferon beta 1a‐1b No direct evidence (very low certainty).
1 finding from 1 review
OR 3.02 [0.27, 33.65]
1 participants
Very low
Intervention not reported
Interferon beta‐1b (Direct evidence; 1 RCT; 372 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention may leads to higher interferon beta‐1b (Direct evidence; 1 RCT; 372 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Interferon beta‐1a (Direct evidence; 2 RCTs; 1457 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention showed no clear difference in interferon beta‐1a (Direct evidence; 2 RCTs; 1457 participants) (moderate certainty).
1 finding from 1 review
OR 1.48 [0.99, 2.2]
1 study · 2 participants
Moderate
Intervention not reported
Laquinimod (Direct evidence; 3 RCTs; 3457 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention showed no clear difference in laquinimod (Direct evidence; 3 RCTs; 3457 participants) (moderate certainty).
1 finding from 1 review
Intervention not reported
Pegylated interferon beta‐1a (Direct evidence; 1 RCT; 1512 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
It is very uncertain whether the intervention changes pegylated interferon beta‐1a (Direct evidence; 1 RCT; 1512… (very low certainty).
1 finding from 1 review
Intervention not reported
Natalizumab (Direct evidence; 1 RCT; 939 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention showed no clear difference in natalizumab (Direct evidence; 1 RCT; 939 participants) (moderate certainty).
1 finding from 1 review
Intervention not reported
Interferon beta 1a‐1b No direct evidence · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…
It is very uncertain whether the intervention changes interferon beta 1a‐1b No direct evidence (very low certainty).
1 finding from 1 review
RR 1.42 [0.78, 2.6]
1 participants
Very low
Intervention not reported
Ocrelizumab No direct evidence · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention showed no clear difference in ocrelizumab No direct evidence (low certainty).
1 finding from 1 review
OR 0.82 [0.42, 1.6]
Studies not reported
Low
Intervention not reported
Ofatumumab No direct evidence · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention may leads to higher ofatumumab No direct evidence (low certainty).
1 finding from 1 review
OR 2 [1.05, 3.81]
Studies not reported
Low
Intervention not reported
Ozanimod No direct evidence · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention showed no clear difference in ozanimod No direct evidence (low certainty).
1 finding from 1 review
OR 1.01 [0.52, 1.95]
Studies not reported
Low
Intervention not reported
Ponesimod No direct evidence · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
It is very uncertain whether the intervention changes ponesimod No direct evidence (very low certainty).
1 finding from 1 review
OR 5.04 [2.15, 11.82]
Studies not reported
Very low
Intervention not reported
Teriflunomide (Direct evidence; 2 RCTs; 2253 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention probably leads to higher teriflunomide (Direct evidence; 2 RCTs; 2253 participants) (moderate certainty).
1 finding from 1 review
Intervention not reported
Placebo · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Intervention (no. of studies/participants) · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Alemtuzumab No direct evidence · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…
It is very uncertain whether the intervention changes alemtuzumab No direct evidence (very low certainty).
1 finding from 1 review
OR 1.52 [0.94, 2.48]
Studies not reported
Very low
Intervention not reported
Cladribine (Direct evidence; 1 RCT; 1326 participants) · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…
It is very uncertain whether the intervention changes cladribine (Direct evidence; 1 RCT; 1326 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Daclizumab (Direct evidence; 1 RCT; 600 participants) · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…
The intervention may leads to higher daclizumab (Direct evidence; 1 RCT; 600 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Interferon beta‐1b (Betaferon) No direct evidence · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…
It is very uncertain whether the intervention changes interferon beta‐1b (Betaferon) No direct evidence (very low certainty).
1 finding from 1 review
RR 0.82 [0.5, 1.33]
1 participants
Very low
Intervention not reported
Dimethylfumarate (Direct evidence; 2 RCTs; 2300 participants) · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…
The intervention showed no clear difference in dimethylfumarate (Direct evidence; 2 RCTs; 2300 participants) (low certainty).
1 finding from 1 review